Literature DB >> 2444080

Microvascular effects of iloprost in the hamster cheek pouch.

B Müller1, M Schmidtke.   

Abstract

In the hamster cheek pouch, microvascular effects of iloprost at a nonhypotensive dose include vasodilatation at the level of arterioles and venules without changes in microvascular permeability, increased number of perfused capillaries/cm2, prevention of microvascular spasm and capillary ischemia as caused by LTD4, and inhibition of histamine- and 5-HT-induced venular leakage of FITC-dextrane. As regards the effects on basal vessel tone, capillary density, and prevention of LTD4 effects, PGE1 had similar effects as also shown by others in the human cutaneous microcirculation. However, PGE1 did not prevent the microvascular leakage caused by histamine. The Ca2+-antagonist nifedipine, apart from arteriolar vasodilatation, neither increased venular diameter and capillary perfusion nor prevented the effects of LTD4 and histamine. The microvascular actions of iloprost by improvement of tissue perfusion and prevention of mediator-induced tissue edema and vasospasm could contribute to the beneficial effects observed in ischemic diseases.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2444080

Source DB:  PubMed          Journal:  Adv Prostaglandin Thromboxane Leukot Res        ISSN: 0732-8141


  3 in total

1.  Is there a place for prostacyclin in the treatment of septic shock?

Authors:  D De Backer
Journal:  Intensive Care Med       Date:  2001-07       Impact factor: 17.440

2.  Intravenous iloprost to recruit the microcirculation in septic shock patients?

Authors:  François Dépret; Alexandre Sitbon; Sabri Soussi; Christian De Tymowski; Alice Blet; Alexandre Fratani; Matthieu Legrand
Journal:  Intensive Care Med       Date:  2017-09-18       Impact factor: 17.440

3.  Prevention and reversal of motor and sensory peripheral nerve conduction abnormalities in streptozotocin-diabetic rats by the prostacyclin analogue iloprost.

Authors:  M A Cotter; K C Dines; N E Cameron
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-05       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.